- socially bharat
- September 27, 2024
Cereno Scientific announces positive topline results of Phase IIa trial with lead candidate CS1 in Pulmonary Arterial Hypertension
Primary endpoint of safety and tolerability met successfully Positive impact on exploratory clinical efficacy parameters: REVEAL risk score: 43% (9/21) of